.Attributes Medication, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Perspective calls for inclusion of patients with MASLD and dimension of liver results in cardio-- kidney-- metabolic trials, when information recommend mechanistically tenable perks as well as professional safety-- and also describes factors to consider for trial design as well as governing commendation.